IG
BMY.RT

ING Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

ING Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-44,276
Closed -$31K – 569
2020
Q4 		$31K Hold
44,276
– – ﹤0.01% 545
2020
Q3 		$100K Hold
44,276
– – ﹤0.01% 475
2020
Q2 		$159K Hold
44,276
– – 0.01% 287
2020
Q1 		$168K Hold
44,276
– – 0.01% 365
2019
Q4 		$133K Buy
+44,276
New +$115K ﹤0.01% 455

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

ING Group's BMY.RT Position: Q1 2021 in Review

ING Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 44,276 shares — an estimated $31K sold.

ING Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $168K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • ING Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • ING Group sold 44,276 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $31K.
  • ING Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • ING Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $168K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on ING Group's 13F filing for Q1 2021, filed 12 May 2021.